EUROPEAN MARKET INTELLIGENCE · JUNE 2026 · UKMC GROUP LTD
The free, verified guide to European medical cannabis investment for family offices, private wealth owners, private equity firms and institutional investors — covering market sizing across six key jurisdictions, regulatory landscape, M&A dynamics, capital flows and where risk-adjusted returns are most compelling in 2026 and 2027.
Published for informational purposes only. Does not constitute financial, legal, investment or regulatory advice. All data sourced from primary government, regulatory and industry sources. Readers should seek independent professional advice before making any investment decision.
THE EUROPEAN MARKET
German medical cannabis market 2025. The largest in Europe. 155% year-on-year growth. Source: Prohibition Partners 2026.
UK medical cannabis market 2025. 103% year-on-year growth. Second largest in Europe by value. Source: Prohibition Partners 2026.
Projected European medical cannabis market size by 2028, driven by Germany, the UK private sector and France's emerging framework. Source: Cannabis Europa April 2026.
Number of European countries with some form of medical cannabis legalisation in 2026. Source: AlphaMaven 2026.
The European medical cannabis investment landscape has undergone a structural transformation between 2021 and 2026. The 2021 peak of cannabis investment optimism — when growth narratives attracted venture capital on the assumption that full European legalisation was two or three years away — proved to be a category error. Investors who priced in rapid regulatory convergence discovered that European cannabis follows the logic of pharmaceutical market development, not technology platform growth — it is slower, more jurisdictionally specific and more defensively valuable once established. The investors who built theses on the medical market alone, grounded in demonstrated prescription revenue and documented patient populations, have outperformed significantly.
The European medical cannabis investment landscape in 2026 is defined by four structural realities: Germany's dominance and its regulatory uncertainty; the UK's high-margin complementary position; Canada's overwhelming supply chain advantage; and the accelerating M&A cycle driven by price compression and operator consolidation.
COUNTRY ANALYSIS
Regulatory assessment: HIGH NEAR-TERM RISK. MedCanG amendments proposing mandatory in-person consultations and mail-order bans working through Bundestag in spring 2026. Federal Cabinet approved draft on 8 October 2025. Near silence since December 2025 first reading per Cannabis Europa London 2026. Investment verdict: Largest revenue pool. Highest near-term regulatory risk. Optimal for patient capital with 3–5 year horizon comfortable with potential 12–18 month contraction period. M&A consolidation is accelerating. EU-GMP certified operators and those with formulary presence and established pharmacy relationships are the highest-quality M&A targets. Source: Prohibition Partners 2026, BfArM.
Regulatory assessment: MEDIUM FUTURE RISK. ACMD review in progress — no legislative proposals introduced as of June 2026. Specialist-only prescribing and CQC oversight already embed clinical governance that Germany's pre-amendment framework lacked. Investment verdict: Highest-quality near-term risk-adjusted entry among European markets. Growing from a lower base with a more defensible regulatory framework. Family offices and PE capital actively deploying in clinic network M&A. Clinic operators with strong CQC ratings, subscription revenue models and established prescriber relationships are the most attractive targets. Source: Prohibition Partners 2026, CQC, GPhC.
Regulatory assessment: POST-RESTRICTION RECOVERY. November 2024 telemedicine restrictions caused acute contraction. Recovery underway via hybrid clinic models. Market is reconstituting around better-governed operators. Investment verdict: Counter-cyclical opportunity for investors with deep sector knowledge. The hybrid clinic operators that enabled Poland's recovery are the most investable assets in the Polish market. Poland's experience is the most instructive case study for evaluating UK and German telemedicine restriction risk. Source: Centrum e-Zdrowia 2025; Prohibition Partners 2026.
Regulatory assessment: MEDIUM RISK — TGA review ongoing. Australia's market is the second largest globally outside North America but faces its own telemedicine and prescribing oversight review, with TGA regulatory reform options expected from early 2026. Investment verdict: Mature market with slower growth and margin pressure from import flood. Domestic producers in particular face difficult economics. Relevant to European investors as a case study for what occurs when supply floods a market before domestic cultivation infrastructure can compete. Source: Australian Office of Drug Control 2025; Prohibition Partners 2026.
Regulatory assessment: PRE-COMMERCIAL — permanent framework finalising. France submitted three documents to the EU for permanent framework approval in March 2025. February 2026 pricing consultation outlined a tiered reimbursement model with four bands: 65%, 30%, 10% or 0% depending on therapeutic benefit. Investment verdict: Significant long-term opportunity given France's population size (the second largest in the EU) and strong healthcare infrastructure. Near-term investable opportunity is limited — no commercial prescribing infrastructure exists and the timeline from framework establishment to meaningful prescription volume will be multi-year. International suppliers seeking market entry must either establish an ANSM-approved French pharmaceutical entity or partner with a registered French exploitant pharmaceutique. Source: Prohibition Partners 2026; ANSM 2025; DGS/DSS consultation February 2026.
Portugal has established itself as Europe's dominant medical cannabis exporter — with 31,021kg exported in 2024 and 33,160kg in the first eight months of 2025 alone. However, a significant and growing proportion of these exports derive from Canadian cultivation imported, processed and re-exported through Portugal. Portugal is increasingly a processing and re-exportation hub rather than a cultivation-led exporter. 2024 export volumes were approximately triple those of the next-largest European exporter, Denmark (9,747kg). Source: Infarmed, Statistics Canada, Prohibition Partners 2026.
SUPPLY CHAIN
"Canada's 2024 cultivation volume plus 2025 start-of-year stock is approximately eight times the maximum cultivation estimates of the rest of the world combined."
— Prohibition Partners Global Medical Cannabis Market Review 2026
Canadian medical cannabis exports reached 275,343 kilograms in 2025 — more than 2.5 times the 2024 volume of 107,632 kilograms. There is an approximate 1.8 million kilogram surplus of cannabis in the global supply chain in 2025. German bulk flower prices have collapsed to €1–€2 per gram for GACP product as a direct result. EU-GMP certified flower still commands a premium but faces increasing price pressure as Canadian producers upgrade their facilities.
For European cannabis investors, this supply chain reality has four direct investment implications:
Businesses competing on bulk product pricing alone face structural margin compression — the Canadian cost advantage is durable and growing.
EU-GMP certification is the minimum quality threshold that protects operators from pure price competition — but it is not sufficient alone. Formulary presence and physician relationships are the durable competitive advantage.
Investors in Portuguese and Danish exporters face a particularly challenging dynamic — their export premium depends on EU-GMP processing capability, but volumes are increasingly sourced from Canadian cultivation rather than domestic. The business is essentially a processing and logistics operation with commodity-level economics.
UK and German clinical operators with proprietary patient data, subscription revenue and established prescriber networks are the most insulated from supply chain commodity pressure — because their value is generated at the patient relationship layer, not the product layer.
M&A DYNAMICS
Family offices and private equity firms are targeting asset-light, profitable companies for M&A — with those at the top of the acquisition target list being operators with well-established pharmacy and prescriber relationships, extensive patient behaviour data and a trusted reputation. The inherent regulatory uncertainty associated with the industry is impacting valuations while driving risk-sharing deal structures — companies that retain development potential under regulatory changes are at an advantage when it comes to M&A targets. Business of Cannabis
After years of anticipation, cross-border M&A activity is genuinely accelerating. High Tide and Curaleaf have made notable European acquisitions, and the transaction pipeline is growing as smaller operators face the reality of compressed margins and limited access to growth capital. Cannabis Europa
The German Federal Court of Justice ruling of 26 March 2026 (I ZR 74/25) has introduced new compliance considerations for M&A transaction structuring in Germany — investors in German cannabis M&A should ensure their legal counsel is briefed on this ruling.
Private equity focused on consolidation plays is typically targeting companies with revenues above €5 million and a clear path to market leadership in a specific geography or product category. Cannabis Europa
International operators (Curaleaf, Tilray, High Tide) acquiring European clinical assets to create prescriber-to-supplier pipelines. Curaleaf's acquisition of Sapphire Medical Clinics (now Curaleaf Clinic) and Tilray's acquisition of Lyphe (now Tilray Lyphe UK Ltd) are the UK examples. Strategic premium paid for clinic network and prescriber relationships.
Private equity targeting operators with revenues above €5 million, strong clinical governance and market leadership potential in Germany or the UK. Deal structures increasingly involve regulatory risk-sharing provisions and deferred consideration tied to regulatory outcome milestones.
Family offices have emerged as the most consistent source of patient capital for European medical cannabis — more consistent than institutional investors or venture capital. Family offices are typically investing at Series A and Series B stages in clinic operators and technology platforms, with longer time horizons than PE and greater tolerance for regulatory uncertainty — but with proportionally stronger governance requirements. Cannabis Europa
INVESTOR FRAMEWORK
Every European cannabis investment thesis built on adult-use legalisation expectation has underperformed. The investors doing well in 2026 built their thesis on the medical market alone — recurring prescription revenue from chronic-condition patients, pharmaceutical-grade clinical infrastructure and defensible regulatory positioning.
Consistent CBPM prescribing driven by physician familiarity and clinical data — not promotional spend — is the most durable competitive advantage in European medical cannabis. Operators with established prescriber relationships and documented clinical outcomes are more valuable than growth-through-marketing operators.
Germany and the UK face very different regulatory risks in 2026. Poland is in recovery. France is pre-commercial. Australia is under TGA review. A portfolio approach that allocates across jurisdictions based on specific regulatory timelines — rather than treating European cannabis as a single asset class — produces better risk-adjusted outcomes.
EU-GMP is now table stakes for operators in the German and UK supply chains. Investors should not pay a premium for EU-GMP certification alone — they should assess what the operator does with that certification in terms of clinical relationships, pricing power and market access.
The near-term German telemedicine decision — expected spring 2026 Bundestag vote — is a binary event that could significantly impact German cannabis asset valuations. Investors with large German positions should assess whether their exposure is sized appropriately relative to this event risk, and whether hedging strategies (regulatory risk provisions, staged investment, deferred consideration) are in place.
THE UK MEDICAL CANNABIS INVESTMENT SUMMIT 2027
The UK Medical Cannabis Investment Summit 2027 brings together family offices, private equity, institutional investors and senior operators from across Europe for two days of verified data, closed-door M&A briefings and direct access to the operators shaping the future of European medical cannabis.
IMPORTANT NOTICE
This page is published by UKMC Group Ltd for informational purposes only and does not constitute financial, legal, investment or regulatory advice.
All data, statistics and regulatory summaries are sourced from publicly available government, regulatory and industry reports as cited. UKMC Group Ltd does not verify the accuracy of third-party data and accepts no liability for any investment decision made on the basis of this content.
The European medical cannabis market is subject to rapid regulatory change. Readers must conduct their own independent due diligence and seek qualified professional advice before making any investment decision.
© 2026 UKMC Group Ltd. All rights reserved.
FREQUENTLY ASKED QUESTIONS